Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 83, Issue 3, Pages 719-730Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2020.03.127
Keywords
actinic keratoses; cutaneous squamous cell carcinoma; field cancerization; keratinocyte carcinoma; solid organ transplant recipient
Categories
Ask authors/readers for more resources
The goal of field cancerization treatment is to reduce the risk of developing keratinocyte carcinoma. Selecting the appropriate therapy depends on the degree of field cancerization and the number of invasive cutaneous squamous cell carcinomas. Other considerations include treatment efficacy, cost, side effects, and patient preference. Field therapies are preferred because they address clinically visible disease and subclinical atypia. However, lesion-directed therapies are useful for lesions that are more difficult to treat or those where a histologic diagnosis is required. Patients with extensive field cancerization benefit from a combination of field-directed and lesion-directed treatments. The second article in this continuing medical education series provides a framework to guide evidence-based decision making for field cancerization treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available